Juventas Therapeutics

Clinical stage company focused on cell therapy with pipeline in hematologic malignancies, solid tumors, and auto-immune diseases. The lead asset is CNCT19, an autologous anti-CD19 CAR-T that is the first CAR-T cell therapy for treatment of B-ALL and has the potential to be the first domestically developed CD19-directed CAR-T therapy specifically approved for B-ALL in China. The drug has obtained a total of 3 INDs from the NMPA. Juventas has partnered with CASI pharmaceutical for global co-commercialization of CNCT19. The company has an extensive pipeline of 10 product candidates with targets such as CD19/CD22, BCMA and EGFR TGF-βKO.